<DOC>
	<DOCNO>NCT01052948</DOCNO>
	<brief_summary>To assess association cabergoline dopamine agonist ( DAs ) , symptomatic , diagnose serious cardiopulmonary disorder , include : 1 . Cardiac valve regurgitation 2 . Diffuse Pleural/pulmonary thicken pericardial retroperitoneal fibrosis 3 . Heart failure 4 . Total , cardiac respiratory mortality</brief_summary>
	<brief_title>The Association Between Dopamine Agonists Cardiac Valvulopathy , Fibrosis Other Cardiopulmonary Events</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Hyperprolactinemia</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Dopamine Agents</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<criteria>At least one year register general practitioner ( GP ) , one year valid data GP , date software conversion ( GP software system change ) meeting criterion one 4 cohort define . rheumatic heart disease congenital heart disease : include structural defect , congenital arrhythmia , cardiomyopathy dilate cardiomyopathy ( congestive cardiomyopathy pericardial , pleural , pulmonary retroperitoneal fibrosis endocarditis myocarditis carcinoid syndrome intravenous drug abuse fibrotic valvular heart disease pleural/pulmonary/pericardial/retroperitoneal fibroses use fenfluramine amiodarone within 3 year prior date diagnosis fibrotic valvular heart disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>dopamine agonist</keyword>
	<keyword>cabergoline</keyword>
	<keyword>Parkinson 's disease</keyword>
	<keyword>hyperprolactinemia</keyword>
	<keyword>epidemiology</keyword>
	<keyword>cardiac valvulopathy</keyword>
</DOC>